AEON Biopharma, Inc. (NASDAQ:AEON) to Post FY2028 Earnings of $0.18 Per Share, HC Wainwright Forecasts

AEON Biopharma, Inc. (NASDAQ:AEON - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 earnings estimates for shares of AEON Biopharma in a research report issued to clients and investors on Wednesday, May 15th. HC Wainwright analyst D. Tsao forecasts that the company will earn $0.18 per share for the year. HC Wainwright currently has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for AEON Biopharma's current full-year earnings is ($1.18) per share.

AEON Biopharma (NASDAQ:AEON - Get Free Report) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.71) EPS for the quarter.

AEON Biopharma Trading Up 2.0 %

Shares of AEON traded up $0.03 during mid-day trading on Friday, reaching $1.53. The stock had a trading volume of 68,151 shares, compared to its average volume of 69,495. AEON Biopharma has a 52-week low of $1.38 and a 52-week high of $17.17. The business's fifty day moving average is $7.38 and its 200 day moving average is $7.36.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Atalaya Capital Management LP purchased a new position in shares of AEON Biopharma during the 3rd quarter worth $19,827,000. Vanguard Group Inc. lifted its position in AEON Biopharma by 261.8% in the first quarter. Vanguard Group Inc. now owns 758,992 shares of the company's stock valued at $8,804,000 after buying an additional 549,207 shares during the last quarter. Finally, Formidable Asset Management LLC acquired a new position in AEON Biopharma in the third quarter valued at about $360,000. 22.78% of the stock is currently owned by hedge funds and other institutional investors.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.